The Pathology and Tissue Core of the Johns Hopkins Lung SPORE program was initiated approximately 14 years ago. The Core activities have evolved over this time period. While the initial emphasis of the Core was to collect frozen tissue samples, services added in response to evolving need of the SPORE include tissue microdissection, collection of specialized samples (lymph nodes, bronchiolaveolar lavage, sputum), expanded data collection and management services, establishing tissue microarrays (TMAs), and pathology consultation for use of human specimens as well as animal models. In addition, the Core has supported the continuous development and refinement of a relational database that provides comprehensive clinical data for all lung cancer patients at the institution in addition to annotation for the pathology specimens in the Core. All of the resources of this Core are leveraged beyond our own SPORE program, as we continue to have active collaborative efforts with investigators at other institutions, including investigators in other SPORE programs. In the past two years, investigators in our program have recognized a need for laboratory models that resemble human lung cancer more closely that do the standard cultured lung cancer cell lines. This prompted the development of a new resource in the Core for establishing transplantable xenografts from clinical samples of human lung cancers. We expect that this resource will contribute significantly to work of investigators throughout the lung cancer research community in coming years, as well as to the projects of our SPORE. Thus, the basic functions of this Core can be summarized as follows: ? Collect, store, and distribute tissues and other biological samples relevant to the study of lung cancer. ? Collect, maintain, and provide access to clinical and pathological data related to all lung cancer patients treated at Johns Hopkins, including those related to these specimens. ? Develop newtransplantable xenograft models of lung cancer from clinical samples ? Provide expert pathologist consultation for molecular studies of human lung cancer and for studies involving rodent models of lung cancer. Relevance to Public Health: This Core provides valuable resources to link laboratory studies to clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058184-18
Application #
8403069
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
18
Fiscal Year
2013
Total Cost
$271,614
Indirect Cost
$90,004
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kim, Jung-Hyun; Thimmulappa, Rajesh K; Kumar, Vineet et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:730-41
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005
Li, Huili; Chiappinelli, Katherine B; Guzzetta, Angela A et al. (2014) Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5:587-98
Wrangle, John; Machida, Emi Ota; Danilova, Ludmila et al. (2014) Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res 20:1856-64
Wrangle, John; Wang, Wei; Koch, Alexander et al. (2013) Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 4:2067-79
Singh, Anju; Happel, Christine; Manna, Soumen K et al. (2013) Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 123:2921-34
Rudin, Charles M; Brahmer, Julie R; Juergens, Rosalyn A et al. (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 8:619-23
Reed, M D; Tellez, C S; Grimes, M J et al. (2013) Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 109:1775-81
Kim, James; Aftab, Blake T; Tang, Jean Y et al. (2013) Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23:23-34

Showing the most recent 10 out of 231 publications